#India #Immunotherapy #Bhubaneswar #Elephas Biosciences #inDNA Life Sciences

Elephas Live Platform Revolutionizes Cancer Treatment in India

In a remarkable development in the field of cancer treatment, the Elephas Live™ Platform has officially been launched for patient screening at inDNA Life Sciences in Bhubaneswar, Odisha, India. This groundbreaking initiative by Elephas Biosciences Corporation aims to enhance access to immunotherapy for cancer patients, a critical need given that cancer is a leading cause of death worldwide, expected to see a dramatic rise in patient numbers by 2060.

The Launch and Its Significance

The first cancer patient was screened using the Elephas Live Platform, marking a significant milestone as this is the first international deployment of the technology. The partnership with inDNA Life Sciences, under the guidance of Dr. Birendranath Banerjee, has paved the way for local implementation of this innovative solution aimed at predicting immunotherapy responses.

The objective of this cooperation is to assess how various Indian cancer patients respond to immunotherapy, potentially altering existing treatment protocols that have an alarmingly low 20% positive response rate. The Elephas Live Platform seeks to improve patient outcomes by providing more accurate predictions, allowing clinicians to match the right therapies with the patients most likely to benefit.

Collaboration and Training

A concerted effort has been made by teams from Elephas and inDNA to ensure the successful installation and utilization of the platform. Extensive training sessions have been conducted for on-site personnel to familiarize them with the technology aims and operations. This collaboration centers around the collection of clinical tissue samples from patients eligible for immunotherapy treatments based on their respective cancer diagnoses.

The Elephas Live Platform utilizes a unique pan-solid tumor technology that ensures treatment effectiveness across various cancer types. The utilization of live patient biopsies preserves the tumor microenvironment, allowing for more precise evaluations of how tumors may react to treatments while also addressing the complexities associated with tumor heterogeneity.

Impact on Cancer Treatment

Maneesh K. Arora, Founder and CEO of Elephas, emphasizes the importance of this milestone, stating, "We are excited to showcase how our technology can predict patient responses to existing immunotherapy treatments. It's a step forward in our commitment to improving cancer outcomes globally." This sentiment is echoed by Dr. Banerjee, who remarked, "Our collaboration with Elephas and our hospital partners aims to eliminate the guesswork in administering immunotherapy, leading to enhanced patient care and overall survival rates."

The Future of Elephas in Cancer Treatment

The Elephas Live platform underscores a significant paradigm shift in the way cancer is treated. By focusing on personalized medicine, Elephas is addressing a critical gap where many patients who could benefit from immunotherapy are currently underserved due to the lack of effective predictive biomarkers.

With a mission to revolutionize how immunotherapy is approached through advanced ex-vivo assessments, Elephas is dedicated to making strides in improving the current landscape of cancer treatment. As the technology matures and more patients benefit from personalized insights into their treatment options, the potential to save lives increases.

For ongoing updates about Elephas and its groundbreaking efforts, you can visit their official website at www.elephas.com and stay connected through LinkedIn.

As more facilities around the globe start to adopt similar technologies, the promise of more effective and personalized cancer therapies may become a reality for countless patients, heralding a new era in the fight against cancer.

Whether this platform is replicated in other regions or further developed, its initial launch in India offers hope not only to patients battling cancer but also to medical professionals dedicated to eradicating the disease across the globe.